Clinical Trial Update: Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating bendamustine in combination with alemtuzumab in patients with pretreated chronic lymphocytic leukemia (CLL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Bendamustine (Bendamustine)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1, Phase 2 | Status: COMPLETED